A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Nivolumab|DRUG: Cabozantinib
Sponsor: Dana-Farber Cancer Institute
Collaborators: Bristol-Myers Squibb|Exelixis